Affibody Medical Investor Relations
Categories:
Navigation:
Non-Regulatory
August 27, 2021
Interim Report – January to June 2021
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®,...
Read more
February 19, 2021
Year End Report 2020
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...
February 21, 2020
Year End Report 2019
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today...
August 23, 2018
Interim Report – January to June 2018
May 18, 2018
Interim Report – January to March 2018
February 23, 2018
Year End Report 2017
November 17, 2017
Interim Report – January to September 2017
August 23, 2017
Interim Report – January to June 2017
May 19, 2017
Interim Report – January to March 2017
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued...
